Related Experiment Video
Updated: Feb 6, 2026

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
Published on: January 17, 2025
Acrylic microparticles increase daptomycin intracellular and in vivo anti-biofilm activity against Staphylococcus
Anne-Kathrin Woischnig1, Lidia M Gonçalves2, Maxime Ferreira3
1Laboratory of Infection Biology, Department of Biomedicine, University and University Hospital Basel, Hebelstrasse 20, 4031 Basel, Switzerland.
Abstract:
Daptomycin (DAP) is a cyclic lipopeptide antibiotic with potential clinical application in orthopedic infections caused by staphylococci. However, it failed to eradicate Staphylococcus aureus in vitro, in intracellular infection studies, as well as in vivo in an experimental model of implant-associated biofilm infections. In this study, the antimicrobial effect of DAP encapsulated in poly(methyl methacrylate)-Eudragit (PMMA-EUD) microparticles (DAP-MPs) on intracellular S. aureus was evaluated in human osteoblast cells using fluorescence in situ hybridization (FISH) analysis. Encapsulated DAP was able to reduce the amount of intracellular S. aureus by 73% compared to blank microparticles (MPs). Then, the advantage of treating with DAP-MPs versus free DAP was evaluated in a murine model of implant-associated biofilm infection. Free DAP showed a >3 log10 decrease in planktonic and adherent bacteria but failed to eradicate adherent methicillin-resistant S. aureus (MRSA), whereas DAP-MPs showed a clearance of planktonic MRSA, significantly reduced adherent MRSA by more than 3 log10 and cured the infection in 60%. This was linked to the prolonged higher DAP concentration within the tissue cage fluid compared to free DAP. To our knowledge, this study provides the first evidence for the high intracellular and in vivo anti-biofilm efficacy of DAP-MPs to target staphylococcal infections.
Insights
Daptomycin microparticles effectively target intracellular Staphylococcus aureus and eradicate implant-associated biofilm infections, offering a promising new treatment for staphylococcal infections.
Area of Science:
- Infectious Diseases
- Biomaterials Science
- Pharmacology
Background:
- Daptomycin (DAP) shows limited efficacy against Staphylococcus aureus, particularly in biofilm and intracellular infections.
- Current treatments struggle to eradicate staphylococcal implant-associated infections.
Purpose of the Study:
- To evaluate the efficacy of daptomycin encapsulated in poly(methyl methacrylate)-Eudragit microparticles (DAP-MPs) against intracellular and biofilm Staphylococcus aureus.
- To compare the therapeutic advantage of DAP-MPs versus free daptomycin in vivo.
Main Methods:
- Antimicrobial effect of DAP-MPs on intracellular S. aureus in human osteoblasts using fluorescence in situ hybridization (FISH).
- In vivo evaluation in a murine model of implant-associated biofilm infection using tissue cage fluid analysis.
Main Results:
- DAP-MPs reduced intracellular S. aureus by 73% compared to blank microparticles.
- DAP-MPs achieved clearance of planktonic MRSA and >3 log10 reduction in adherent MRSA, curing 60% of infections.
- Prolonged higher daptomycin concentration in tissue cage fluid was observed with DAP-MPs.
Conclusions:
- Daptomycin microparticles demonstrate significant intracellular and in vivo anti-biofilm efficacy against staphylococcal infections.
- DAP-MPs represent a novel and effective strategy for treating challenging staphylococcal implant-associated infections.
More Related Videos
08:08The Use of Drip Flow and Rotating Disk Reactors for Staphylococcus aureus Biofilm Analysis
Published on: December 27, 2010
06:36Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds
Published on: September 8, 2021
Related Concept Videos
Intracellular Signaling Cascades
Increasing Function
Biofilms
Increased Body Temperature
Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Primary Active Transport